ARTICLE | Company News
SGEN, Proacta cancer licensing deal
October 22, 2001 7:00 AM UTC
Seattle Genetics (SGEN) received exclusive worldwide rights from Proacta Therapeutics (Auckland, New Zealand) to a set of cytotoxic therapeutics that target the minor groove of DNA. SGEN will evaluate...